This insider cluster is too small to warrant a directional trade. Monitor for any upcoming earnings or pipeline catalysts (e.g., ZORYVE label expansion) that could drive the stock, but ignore this selling as noise.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 25 $24.86entry
- T+1 · 3mo ago +1.13%α +1.10% · $25.14
- T+5 · 3mo ago −4.46%α −3.93% · $23.75
- T+20 · 8w ago +6.11%α +5.87% · $26.38
- T+58 · todayOpen
- T+60 · tomorrow Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three insiders at Arcutis Biotherapeutics sold a total of $198K in open-market sales over a 7-day window, with the largest sale ($124K) by Director Howard Welgus. The total value is only ~0.006% of the company's $3.2B market cap, making this a trivial cluster by proportionality. No cross-filing context suggests distress or material negative news; the cluster is neutral and low-impact.
Key Financial Metrics
Key Facts
- Three insiders sold shares totaling $198K in open-market sales from Aug 13-20, 2026.
- Total sales represent only ~0.006% of Arcutis's $3.2B market cap, well below the 0.1% materiality threshold.
- Director Howard Welgus accounted for the largest sale at $124K; Director Terrie Curran also exercised non-cash derivatives.
- No cross-filing context indicates distress, earnings miss, or material negative news.
Financial Impact
Total insider sales of $198K, or ~0.006% of market cap, immaterial.
Risk Factors
- Insider sales could accelerate if insiders perceive the stock as fully valued near $26-27.
- No material risk from this cluster; the primary risk is the company's execution on its commercial-stage dermatology pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARQT-1787615130398 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers